INS and Hypoglycemia: Over recent years, newer second-generation basal insulins (2BIs), particularly insulin glargine U300 (Gla-300) and insulin degludec U100 (Deg-100) have been developed to improve glycemic control, reduce hypoglycemia risk, offer more flexible dosing options.